JAVIER ALBERTO CARBONE CAMPOVERDE-rekin lankidetzan egindako argitalpenak (14)

2021

  1. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations

    Journal of Allergy and Clinical Immunology, Vol. 148, Núm. 5, pp. 1332-1341.e5

2020

  1. Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 8, Núm. 10, pp. 3342-3347

  2. Executive Summary of the Consensus Document on the Diagnosis and Management of Patients with Primary Immunodeficiencies

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 9, pp. 438-443

2016

  1. Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency

    Clinical Immunology, Vol. 169, pp. 80-84

2014

  1. Experience in IVIg therapy for selected women with recurrent reproductive failure and NK cell expansion

    American Journal of Reproductive Immunology, Vol. 71, Núm. 5, pp. 458-466

2013

  1. New decision-tree model for defining the risk of reproductive failure

    American Journal of Reproductive Immunology, Vol. 70, Núm. 1, pp. 59-68

2012

  1. Intravenous Immunoglobulin Treatment Increased Live Birth Rate in a Spanish Cohort of Women with Recurrent Reproductive Failure and Expanded CD56 + Cells

    American Journal of Reproductive Immunology, Vol. 68, Núm. 1, pp. 75-84

  2. The European internet-based patient and research database for primary immunodeficiencies: Update 2011

    Clinical and Experimental Immunology, Vol. 167, Núm. 3, pp. 479-491

2011

  1. Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: Immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome

    Clinical and Experimental Immunology, Vol. 164, Núm. 1, pp. 100-107

2006

  1. Efficacy and safety of Etanercept, high-dose intravenous gammaglobulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy

    Lupus, Vol. 15, Núm. 12, pp. 881-885

2005

  1. Discordance between anti-β2-glycoprotein-I and anti-cardiolipin antibodies in patients with clinical criteria of antiphospholipid syndrome

    Clinical and Experimental Rheumatology, Vol. 23, Núm. 4, pp. 525-528

  2. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency

    Annals of the New York Academy of Sciences

2001

  1. Antiphospholipid antibodies: A risk factor for occlusive retinal vascular disorders. Comparison with ocular inflammatory diseases

    Journal of Rheumatology, Vol. 28, Núm. 11, pp. 2437-2441

1999

  1. Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss

    Lupus, Vol. 8, Núm. 4, pp. 274-278